(This blog was derived from a presentation featuring Michelle Lott and Renae Franz from leanRAQA and Fernada Nusbaum from TTi. You can watch the full webinar here: https://youtu.be/JlUPDJyp76U)
Most medtech founders believe their biggest hurdle is FDA clearance. They think that once that magical letter arrives, the clouds part, the sales roll in, and the commercialization engine hums like it was waiting breathlessly for permission.
If only.
All to often, it’s made painfully (and even sometimes hilariously) clear that medtech companies don’t fail because the technology wasn’t innovative enough. They fail because their regulatory, reimbursement, and commercialization plans grew up in silos—and no one notices until money is gone, timelines are blown, and someone on the leadership team has developed a small but permanent facial twitch.
Ask any regulatory consultant, and they’ll tell you: the role often doubles as grief counseling, guiding medtech founders through the full emotional cycle—confusion, anger, denial, bargaining—because they waited too long to do the right things, in the right order.
And once you’re rebuilding documentation retroactively, grief starts to feel like an efficient descriptor.
The heart of the problem is timing. Companies often hold off on regulatory and reimbursement planning because it “sounds expensive.” The irony is that what’s actually expensive is having to rebuild your entire engineering file, test strategy, or evidence plan retroactively because you didn’t set the right foundation. But without early alignment, teams wind up redoing engineering files, rewriting claims, rebuilding evidence plans, or walking back design decisions that no longer support the pathway they thought they were pursuing. And if any of those happen in the wrong order—or not at all—they can derail every milestone that follows.
And then there’s reimbursement—the part everyone swears they’ll get to “later,” as if payers operate on founder optimism. Reimbursement revolves around three pillars—coding, coverage, and payment. Misunderstanding any of them can be fatal, because reimbursement strategies aren’t built in months. They’re built in years, and new technology does not automatically equal new payment. In fact, many companies discover far too late that the code they planned around doesn’t apply to the site of service where their device is actually used. One startup learned this the hard way: their chosen CPT code supported a procedure that had been obsolete for a decade. With no way to get paid for the real clinical scenario, the company folded.
This is where claims come in. Most teams love describing what their device can do. But the FDA loves those descriptions only if you can prove every word—with evidence, risk analysis, and clinical logic. A single adjective can turn a 510(k) into a de novo, a manageable study into a multi-year burden, or a promising reimbursement story into a dead end. Claims don’t just guide FDA classification; they influence payment, coding, coverage, and clinician perception.
In other words: your future success is sitting inside the grammar of your claims.
But that doesn’t mean that the most complicated path to market is always the best choice. A company developed a diagnostic device for eye disease, and their early ambitions pointed them toward a de novo—a long, expensive road. But after aligning their regulatory, reimbursement, and commercial strategies, they discovered a more modest initial claim that fell under Class I – no 510(k), no de novo. And, critically, reimbursement already existed. They entered the market faster, generated revenue, and built evidence to expand their claims over time. A classic “crawl, walk, run” success.
Contrast that with the typical founder mindset: “Once we clear FDA, we’re golden.” But that’s backward. Risk actually spikes after regulatory clearance. Reimbursement, economic evidence, payer behavior, site-of-service dynamics, clinician adoption—these become the new bottlenecks. Investors know this. Hospitals know this. Most early-stage teams don’t. And once you’re in the market, gaps get more expensive—not less.
So what does smart strategy look like?
It looks like cross-functional alignment before prototypes harden, before claims calcify, and before evidence plans are locked into budgets. It includes talking to real users early—not for validation theatre, but to capture true user needs, which become the backbone of every requirement that follows. It includes mapping regulatory expectations directly into engineering documents. It includes verifying whether reimbursement codes actually match the real-world clinical workflow. And it includes understanding payer logic well enough to avoid building evidence that satisfies FDA but leaves payers unimpressed.
One of the most valuable tools discussed is the trace matrix—not the one most engineers know, but a broader version: a cross-functional line of sight from user needs to claims, regulatory pathway, reimbursement strategy, evidence plan, and commercial messaging. It forces alignment early, protects teams from wishful thinking, and exposes weak assumptions before they become expensive mistakes.
The key takeaway? Start aligning regulatory, reimbursement, and commercialization early—then keep doing it throughout development, and your strategy should always be intentional, not accidental:
-
define claims early and validate them with users
-
select a regulatory path based on evidence needs and payer expectations, not guesswork
-
verify coding options and site-of-service assumptions
-
build early economic arguments for payers and hospitals
-
use tools like a trace matrix to align engineering, clinical, regulatory, reimbursement, and commercialization needs before product decisions solidify
It sounds obvious, but the absence of this mindset costs medtech companies millions each year. Not because the FDA is harsh (although they can be), or because payers are impossible (although they can be), but because misalignment—quiet, slow-moving, seemingly harmless—accumulates until it breaks the entire pathway.
Early planning isn’t just wise—it’s usually cheaper, and a thoughtful pathway can shave months or even years off development and significantly increase investor confidence.
If you’re building a device and haven’t yet asked, “Does our regulatory plan match our reimbursement reality and our commercial goals?”, now is the time. The earlier you ask, the fewer bruises you’ll collect along the way.
No single blog—or regulation—captures the full complexity of bringing a medical device to market. The landscape is dynamic by design.
If you’re continuing to build your perspective, you may find these additional resources useful:
Each approaches the topic from a slightly different angle—strategic, operational, and practical.
In my experience, regulatory excellence isn’t achieved through one-time effort—it’s built through continuous learning and disciplined execution.
